RxDoctor Payments Data

Jared Corriel, MD

Cardiovascular Disease · Valley Cottage, NYNPI 1518108182

Payments from drug & device makers

$17,994in general payments, 2019–2025

Across 642 payments — averaging $28.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$4K
  • Medtronic$2K
  • Pfizer$1K
  • Johnson & Johnson$953
  • AstraZeneca$899
  • Novartis$827
  • plus $8K from 43 others

What the payments were for

  • Travel & lodging$1,0036%
  • Food & beverage$16,93594%
  • Education$560%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$17,994 in reported general payments places this provider in the 85th percentile of 2,302 cardiovascular disease providers in New York.

See all cardiovascular disease providers in New York

Medicare billing

Part B allowed, 2024
$545,274
Medicare patients
1,841
Services billed
6,440

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban321$433,913
XareltoRivaroxaban175$231,330
Repatha SureclickEvolocumab165$157,305
EntrestoSacubitril/Valsartan112$133,580
FarxigaDapagliflozin Propanediol58$73,501
MultaqDronedarone Hcl37$54,868
JardianceEmpagliflozin27$35,433
Praluent PenAlirocumab26$24,817
OzempicSemaglutide11$14,387
EdarbiAzilsartan Medoxomil27$14,149
Nebivolol Hcl158$11,680
Valsartan391$11,358
Metoprolol Succinate731$9,950
Rosuvastatin Calcium699$9,939
Atorvastatin Calcium646$7,752

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$1,132$433,913321 claims
Johnson & JohnsonXarelto$953$231,330175 claims
NovartisEntresto$827$133,580112 claims
AstraZenecaFarxiga$899$73,50158 claims
Sanofi-aventis U.S. LLCMultaq$192$54,86837 claims
Boehringer IngelheimJardiance$700$35,43327 claims
Novo NordiskOzempic$540$14,38711 claims
Arbor Pharmaceuticals, Inc.Edarbi$376$14,14927 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,302 cardiovascular disease providers in New York.

Other cardiovascular disease in Valley Cottage

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →